Trial Profile
A Pilot Study Examining the Impact of the Jak1 Inhibitor Itacitinib on the Sarcoma Tumor Immune Microenvironment
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Itacitinib (Primary)
- Indications Chondrosarcoma; Leiomyosarcoma; Malignant fibrous histiocytoma; Myxoid liposarcoma; Synovial sarcoma
- Focus Pharmacodynamics
- 08 Apr 2024 Planned End Date changed from 31 Mar 2024 to 2 May 2024.
- 04 Jan 2024 Planned End Date changed from 1 Dec 2023 to 31 Mar 2024.
- 25 Aug 2023 Planned End Date changed from 1 Jan 2025 to 1 Dec 2023.